drugset / Trial / NCT04959500
Newly Diagnosed Glioblastoma
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma.Take PFS as the main evaluation index, the purpose is to evaluate its effectiveness
Timeline
- Start
- 2021-07-21
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | — |
| Background | Temozolomide | Small molecule | 200 mg/m2 | — |